PMID- 32756149
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 31
DP  - 2020 Jul 31
TI  - Clinical remission of a critically ill COVID-19 patient treated by human 
      umbilical cord mesenchymal stem cells: A case report.
PG  - e21429
LID - 10.1097/MD.0000000000021429 [doi]
LID - e21429
AB  - RATIONALE: The COVID-19 cases increased very fast in January and February 2020. 
      The mortality among critically ill patients, especially the elder ones, is 
      relatively high. Considering many patients died of severe inflammation response, 
      it is urgent to develop effective therapeutic strategies for these patients. The 
      human umbilical cord mesenchymal stem cells (hUCMSCs) have shown good 
      capabilities to modulate the immune response and repair the injured tissue. 
      Therefore, investigating the potential of hUCMSCs to the treatment of COVID-19 
      critically ill patients is necessary. PATIENT CONCERNS: A 65-year-old woman felt 
      fatigued and had a fever with body temperature of 38.2C, coughed up white foaming 
      sputum. After 1 day, she had chest tightness with SPO2 of 81%, and blood pressure 
      of 160/91 mm Hg. DIAGNOSE: According to the guideline for the diagnosis and 
      treatment of 2019 novel coronavirus infected pneumonia (Trial 4th Edition), 
      COVID-19 was diagnosed, based on the real-time RT-PCR test of SARS-CoV-2. 
      INTERVENTIONS: After regular treatment for 12 days, the inflammation symptom of 
      the patient was still very severe and the potential side effects of 
      corticosteroid were observed. Then, allogenic hUCMSCs were given 3 times (5 x 10 
      cells each time) with a 3-day interval, together with thymosin alpha1 and antibiotics 
      daily injection. OUTCOMES: After these treatments, most of the laboratory indexes 
      and CT images showed remission of the inflammation symptom. The patient was 
      subsequently transferred out of ICU, and the throat swabs test reported negative 
      4 days later. LESSONS: These results indicated the clinical outcome and good 
      tolerance of allogenic hUCMSCs transfer.
FAU - Liang, Bing
AU  - Liang B
AD  - Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
FAU - Chen, Junhui
AU  - Chen J
AD  - Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, 
      Shenzhen.
FAU - Li, Tao
AU  - Li T
AD  - Yunnan Yasheng Medical Technology Co., Ltd.
FAU - Wu, Haiying
AU  - Wu H
AD  - Emergency Department of the First Affiliated Hospital of Kunming Medical 
      University, EICU/MICU.
FAU - Yang, Wenjie
AU  - Yang W
AD  - Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
FAU - Li, Yanjiao
AU  - Li Y
AD  - Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases & Yunnan Stem 
      Cell Translational Research Center, Kunming University.
FAU - Li, Jianchun
AU  - Li J
AD  - Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
FAU - Yu, Congtao
AU  - Yu C
AD  - Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, 
      Shenzhen.
FAU - Nie, Fangang
AU  - Nie F
AD  - Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
FAU - Ma, Zhaoxia
AU  - Ma Z
AD  - Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases & Yunnan Stem 
      Cell Translational Research Center, Kunming University.
AD  - Yunnan Jici Institute for Regenerative Medicine Co., Ltd., Kunming.
FAU - Yang, Mingxi
AU  - Yang M
AD  - Department of Critical Care Medicine, Baoshan People's Hospital, Baoshan.
FAU - Xiao, Mingying
AU  - Xiao M
AD  - Department of Infectious Diseases.
FAU - Nie, Panrong
AU  - Nie P
AD  - Department of Neonatology, Baoshan People's Hospital, Baoshan.
FAU - Gao, Yanfeng
AU  - Gao Y
AD  - Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, 
      Shenzhen.
AD  - School of Life Sciences, Zhengzhou University, Zhengzhou, China.
FAU - Qian, Chuanyun
AU  - Qian C
AD  - Emergency Department of the First Affiliated Hospital of Kunming Medical 
      University, EICU/MICU.
FAU - Hu, Min
AU  - Hu M
AUID- ORCID: 0000-0002-9533-1384
AD  - Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, 
      Shenzhen.
AD  - Yunnan Key Laboratory for Basic Research on Bone and Joint Diseases & Yunnan Stem 
      Cell Translational Research Center, Kunming University.
AD  - Boten International Stem Cell Hospital, Boten, Laos.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Bacterial Agents)
RN  - W0B22ISQ1C (Thymalfasin)
SB  - IM
MH  - Aged
MH  - Anti-Bacterial Agents/therapeutic use
MH  - *Betacoronavirus
MH  - COVID-19
MH  - Combined Modality Therapy
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Coronavirus Infections/drug therapy/*therapy/virology
MH  - Female
MH  - Humans
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Pandemics
MH  - Pneumonia, Viral/*therapy/virology
MH  - SARS-CoV-2
MH  - Thymalfasin/therapeutic use
MH  - Treatment Outcome
MH  - COVID-19 Drug Treatment
PMC - PMC7402800
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/08/07 06:00
MHDA- 2020/08/25 06:00
PMCR- 2020/07/31
CRDT- 2020/08/07 06:00
PHST- 2020/08/07 06:00 [entrez]
PHST- 2020/08/07 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/07/31 00:00 [pmc-release]
AID - 00005792-202007310-00079 [pii]
AID - MD-D-20-02492 [pii]
AID - 10.1097/MD.0000000000021429 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jul 31;99(31):e21429. doi: 
      10.1097/MD.0000000000021429.